<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="80% required pharmacotherapy or symptomatic therapy. The median time of" exact="treatment" post="of specific viral infection ranged from 7 (for EBV)"/>
 <result pre="symptomatic therapy. The median time of treatment of specific viral" exact="infection" post="ranged from 7 (for EBV) to 24 (for CMV)"/>
 <result pre="unrelated donor (MMUD)-HCT. The risk factor for death from viral" exact="infection" post="were CMV-IgG seropositivity in acute lymphoblastic leukemia recipient, and"/>
 <result pre="acute lymphoblastic leukemia recipient, and MUD/MMUD-HCT. The incidence of EBV" exact="infection" post="requiring pre-emptive treatment with rituximab in allo-HCT children was"/>
 <result pre="recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive" exact="treatment" post="with rituximab in allo-HCT children was 19.3%. In 30.8%"/>
 <result pre="of EBV infection, these episodes were preceded by other viral" exact="infection" post="and treated with antivirals, which did not prevent development"/>
 <result pre="did not prevent development of EBV-DNA-emia with need of rituximab" exact="treatment" post="in 81.5% cases. In 47.7% of these cases, GVHD"/>
 <result pre="or lymphoma in pediatric auto-HCT setting.5 The incidence of viral" exact="infection" post="after allo-HCT was observed in 19.3% of patients during"/>
 <result pre="with median onset of 10 days post-transplant.5 Viruses that cause" exact="infection" post="after HCT can be classified as latent or &quot;episodic&quot;"/>
 <result pre="herpes simplex virus (HSV) reactivation was the most frequent viral" exact="infection" post="both in allo-HCT and auto-HCT patients.4,5 Overall, 8% of"/>
 <result pre="outcomes were associated with the application of drugs and molecular" exact="tests" post="to detect and prevent early bacterial infections, HSV, cytomegalovirus"/>
 <result pre="(CMV), and pre-engraftment candidal infections.6 Screening for reactivation with pre-emptive" exact="treatment" post="or application of prophylaxis in seropositive recipients plays a"/>
 <result pre="was given to antiviral drugs usage and incidence of EBV" exact="infection" post="after HCT. Materials and Methods Design of the Study"/>
 <result pre="viruses polymerase chain reaction (PCR)-based analysis was used for the" exact="diagnosis" post="of viral infections of material derived from blood, urine,"/>
 <result pre="infections with CMV and EBV in allo-HCT patients.8,9 Recurrent viral" exact="infection" post="was defined as a new episode of viral infection"/>
 <result pre="viral infection was defined as a new episode of viral" exact="infection" post="in a patient with previous evidence of the same"/>
 <result pre="in a patient with previous evidence of the same viral" exact="infection" post="in whom the virus has not been detected for"/>
 <result pre="detected for at least 4 weeks during active surveillance. Recurrent" exact="infection" post="could have resulted from reactivation of latent virus or"/>
 <result pre="of significant CMV-DNA-emia and EBV-DNA-emia and/or CMV- or EBV-disease, specific" exact="treatment" post="was implemented. Statistical Analysis An event was defined as"/>
 <result pre="was implemented. Statistical Analysis An event was defined as the" exact="diagnosis" post="of a first specific infectious disorder. Categorical variables were"/>
 <result pre="viral infections in allo-HCT setting. In the allo-HCT setting, viral" exact="infection" post="with a single pathogen occurred in 54.0% of patients,"/>
 <result pre="(10/48), BKV (5/48) infections (Table 1). The median time of" exact="treatment" post="of specific viral infection range from 7 days for"/>
 <result pre="(Table 1). The median time of treatment of specific viral" exact="infection" post="range from 7 days for EBV, RV, FLUAV, RhV,"/>
 <result pre="EBV and ADV) survival rate ranged between 90.3% for ADV" exact="infection" post="and 95.4 for EBV infection and did not differ"/>
 <result pre="ranged between 90.3% for ADV infection and 95.4 for EBV" exact="infection" post="and did not differ between specific viral infection (p=0.3)"/>
 <result pre="for EBV infection and did not differ between specific viral" exact="infection" post="(p=0.3) (Figure 2A). With respect to primary diagnosis, survival"/>
 <result pre="(Figure 2A). With respect to primary diagnosis, survival from viral" exact="infection" post="was 97.4% (95% CI=95.9–98.9) in AML and 92.4% (95%"/>
 <result pre="p&amp;lt;0.001), acute and chronic graft versus host disease (a/cGVHD) before" exact="infection" post="(HR=1.9; p&amp;lt;0.001 and HR=3.4; p&amp;lt;0.001, respectively) (Table 2). Table"/>
 <result pre="Of 175 EBV infectious episodes, in 66 (37.7%) cases, the" exact="infection" post="was preceded by another viral infection, including CMV (n=21),"/>
 <result pre="n=1; ADV+RV, n=1) within 7–56 (median 24) days before the" exact="diagnosis" post="of EBV-DNA-emia. In 54/66 (81.8%) cases, a significant EBV-DNA-emia"/>
 <result pre="In 54/66 (81.8%) cases, a significant EBV-DNA-emia has occurred and" exact="treatment" post="with rituximab was required. In 44/54 (81.5%) of these"/>
 <result pre="In 44/54 (81.5%) of these cases viral infections preceding EBV" exact="infection" post="were treated with antiviral drugs, including: CDV (n=18), GCV"/>
 <result pre="(FCV+GCV, n=5; FCV+CDV, n=2; GCV+CDV, n=2). Antivirals were used for" exact="treatment" post="of: CMV (n=16), BKV (n=11), ADV (n=4), FLUAV (n=1),"/>
 <result pre="CMV infection.10 Monitoring by a sensitive technique such as PCR" exact="tests" post="of whole blood allows intervention before development of CMV"/>
 <result pre="treatment.18 Nevertheless, management of patients with resistant or refractory CMV" exact="infection" post="or CMV disease is a challenge. Combination therapy (ganciclovir"/>
 <result pre="reduced, if possible.18 We observed that cumulative incidence of BKV" exact="infection" post="was 23.8% with survival rate of 90.7%. Cesaro et"/>
 <result pre="study cidofovir was the most frequently used drug in the" exact="treatment" post="of BKV infection. Cidofovir at a dose of 3–5"/>
 <result pre="times/week without probenecid, were used by other authors for the" exact="treatment" post="of BKV hemorrhagic cystitis, although without strong recommendation on"/>
 <result pre="(6–28% vs 0–6%, respectively);20 we observed 10.7% incidence of ADV" exact="infection" post="with 90.3% survival rate. A relatively low percentage of"/>
 <result pre="0.4% among auto-HCT.22 However, in that time period, viral antigen" exact="detection" post="by immunofluorescence or enzyme immunoassays were used in diagnostics.22"/>
 <result pre="diagnostics.22 During the last decade, rapid and highly sensitive molecular" exact="tests" post="have been developed and made available, with the most"/>
 <result pre="the 4th European Conference of Infections in Leukemia (ECIL-4) recommend" exact="diagnosis" post="based on PCR of material collected from the respiratory"/>
 <result pre="deaths were observed. In other studies the incidence of RV" exact="infection" post="varied from 2.3% in adult allo-HCT and auto-HCT recipients"/>
 <result pre="12.9% with no NoV-related mortality.26 PCR as well virus antigen" exact="detection" post="in stool are commonly used in diagnosis of RV"/>
 <result pre="well virus antigen detection in stool are commonly used in" exact="diagnosis" post="of RV and NoV infection. No specific prophylaxis against"/>
 <result pre="were used in some studies.24,27 In immunocompetent individuals primary EBV" exact="infection" post="or reactivation induces usually asymptomatic infection or infectious mononucleosis.28"/>
 <result pre="immunocompetent individuals primary EBV infection or reactivation induces usually asymptomatic" exact="infection" post="or infectious mononucleosis.28 In immunocompromised patients most EBV reactivations"/>
 <result pre="of immunosuppressive regimens used.30 We observed high incidence of EBV" exact="infection" post="(22.7%) in allo-HCT patients, while there were no cases"/>
 <result pre="of EBV reactivations, these episodes were preceded by other viral" exact="infection" post="treated with antivirals, which did not prevent the development"/>
 <result pre="be closely monitored for symptoms and/or signs attributable to EBV" exact="infection" post="and PTLD.8 The following pre-emptive therapies are recommended after"/>
 <result pre="and MUD/MMUD-HCT were the risk factors for deaths from viral" exact="infection" post="in children after HCT. This is a unique observation,"/>
 <result pre="auto-HCT patients viral infections were episodic. The most frequent viral" exact="infection" post="after allo-HCT were CMV, BKV and EBV. Most viral"/>
 <result pre="80% required pharmacotherapy or symptomatic therapy. The median time of" exact="treatment" post="of specific viral infection ranged from 7 (for EBV)"/>
 <result pre="symptomatic therapy. The median time of treatment of specific viral" exact="infection" post="ranged from 7 (for EBV) to 24 days (for"/>
 <result pre="mortality was observed in case of CMV infection, whereas primary" exact="diagnosis" post="did not influence survival from viral infection. The risk"/>
 <result pre="MUD/MMUD vs MSD. The risk factor for death from viral" exact="infection" post="were CMV-IgG seropositivity in acute lymphoblastic leukemia recipients, MUD/MMUD"/>
 <result pre="lymphoblastic leukemia recipients, MUD/MMUD vs MSD. The incidence of EBV" exact="infection" post="requiring pre-emptive treatment with rituximab in allo-HSCT children was"/>
 <result pre="MUD/MMUD vs MSD. The incidence of EBV infection requiring pre-emptive" exact="treatment" post="with rituximab in allo-HSCT children was 19.3%. In 30.8%"/>
 <result pre="of EBV infection, these episodes were preceded by other viral" exact="infection" post="treated with antivirals, which did not prevent development of"/>
 <result pre="prevent development of significant EBV-DNA-emia with the need of rituximab" exact="treatment" post="in 81.5% of cases. This is clinically proven evidence"/>
 <result pre="Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for" exact="diagnosis" post="and treatment of human respiratory syncytial virus, parainfluenza virus,"/>
 <result pre="Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and" exact="treatment" post="of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus,"/>
 <result pre="CamaraR, RobinC, et al. Guidelines for the management of cytomegalovirus" exact="infection" post="in patients with haematological malignancies and after stem cell"/>
 <result pre="DalianisT, Hanssen RinaldoC, et al. ECIL guidelines for the prevention," exact="diagnosis" post="and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic"/>
 <result pre="RinaldoC, et al. ECIL guidelines for the prevention, diagnosis and" exact="treatment" post="of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell"/>
 <result pre="2018;73(1):12–21. doi:10.1093/jac/dkx32429190347 20.Matthes-MartinS, FeuchtingerT, ShawPJ, et al. European guidelines for" exact="diagnosis" post="and treatment of adenovirus infection in leukemia and stem"/>
 <result pre="20.Matthes-MartinS, FeuchtingerT, ShawPJ, et al. European guidelines for diagnosis and" exact="treatment" post="of adenovirus infection in leukemia and stem cell transplantation:"/>
 <result pre="et al. European guidelines for diagnosis and treatment of adenovirus" exact="infection" post="in leukemia and stem cell transplantation: summary of ECIL-4"/>
 <result pre="Infect Dis. 2013;15(3):219–232. doi:10.1111/tid.2013.15.issue-323363310 24.FlerlageT, HaydenR, CrossSJ, et al. Rotavirus" exact="infection" post="in pediatric allogeneic hematopoietic cell transplant recipients: clinical course"/>
 <result pre="Marrow Transplant. 2000;26(3):299–303. doi:10.1038/sj.bmt.170248410967569 26.RoblesJD, CheukDK, HaSY, ChiangAK, ChanGC. Norovirus" exact="infection" post="in pediatric hematopoietic stem cell transplantation recipients: incidence, risk"/>
 <result pre="J Oncol Pharm Pract. 2015;21(3):238–240. doi:10.1177/107815521452231324658362 28.LinR, LiuQ. Diagnosis and" exact="treatment" post="of viral diseases in recipients of allogeneic hematopoietic stem"/>
 <result pre="Leuk Lymphoma. 2013;54(3):503–506. doi:10.3109/10428194.2012.71834222873830 30.StyczynskiJ, EinseleH, GilL, LjungmanP. Outcome of" exact="treatment" post="of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem"/>
</results>
